ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Clinical trials for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE explained in plain language.

Never miss a new study

Get alerted when new ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE trials appear

Sign up with your email to follow new studies for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Extended treatment trial for rare immune disease halted

Disease control Terminated

This study aimed to provide long-term treatment with CDZ173 to patients with APDS/PASLI, a rare genetic immune disorder. It followed patients who had previously participated in related studies to monitor the drug's safety and effectiveness over time. The study was terminated and …

Matched conditions: ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Phase: PHASE2, PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control

Last updated Apr 02, 2026 13:12 UTC

ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Get alerted when new ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE trials appear

Extended treatment trial for rare immune disease halted